RESUMEN
Alkaptonuria (AKU, OMIM, No. 203500) is a rare, slow-progressing, irreversible, multisystemic disease resulting from a deficiency of the homogentisate 1,2-dioxygenase enzyme, which leads to the accumulation of homogentisic acid (HGA) and subsequent deposition as pigment in connective tissues called ochronosis. As a result, severe arthropathy of large joints and spondyloarthropathy with frequent fractures, ligament ruptures, and osteoporosis develops in AKU patients. Since 2020, the first-time treatment with nitisinone has become available in the European Union. Nitisinone significantly reduces HGA production and arrests ochronosis in AKU patients. However, blocking of the tyrosine metabolic pathway by the drug leads to tyrosine plasma and tissue concentrations increase. The nitisinone-induced hypertyrosinemia can lead to the development of corneal keratopathy, and once it develops, the treatment needs to be interrupted. A decrease in overall protein intake reduces the risk of the keratopathy during nitisinone-induced hypertyrosinemia in AKU patients. The low-protein diet is not only poorly tolerated by patients, but over longer periods, leads to a severe muscle loss and weight gain due to increased energy intake from carbohydrates and fats. Therefore, the development of novel nutritional approaches is required to prevent the adverse events due to nitisinone-induced hypertyrosinemia and the negative impact on skeletal muscle metabolism in AKU patients.
Asunto(s)
Alcaptonuria , Ocronosis , Tirosinemias , Humanos , Alcaptonuria/tratamiento farmacológico , Alcaptonuria/metabolismo , Ocronosis/tratamiento farmacológico , Tirosina/uso terapéutico , Ácido Homogentísico/metabolismoRESUMEN
Alkaptonuria (AKU) is a rare genetic autosomal recessive disorder characterized by elevated serum levels of homogentisic acid (HGA). In this disease, tyrosine metabolism is interrupted because of the alterations in homogentisate dioxygenase (HGD) gene. The patient suffers from ochronosis, fractures, and tendon ruptures. To date, no medicine has been approved for the treatment of AKU. However, physiotherapy and strong painkillers are administered to help mitigate the condition. Recently, nitisinone, an FDA-approved drug for type 1 tyrosinemia, has been given to AKU patients in some countries and has shown encouraging results in reducing the disease progression. However, this drug is not the targeted treatment for AKU, and causes keratopathy. Therefore, the foremost aim of this study is the identification of potent and druggable inhibitors of AKU with no or minimal side effects by targeting 4-hydroxyphenylpyruvate dioxygenase. To achieve our goal, we have performed computational modelling using BioSolveIT suit. The library of ligands for molecular docking was acquired by fragment replacement of reference molecules by ReCore. Subsequently, the hits were screened on the basis of estimated affinities, and their pharmacokinetic properties were evaluated using SwissADME. Afterward, the interactions between target and ligands were investigated using Discovery Studio. Ultimately, compounds c and f were identified as potent inhibitors of 4-hydroxyphenylpyruvate dioxygenase.
Asunto(s)
4-Hidroxifenilpiruvato Dioxigenasa , Alcaptonuria , Ocronosis , Humanos , Alcaptonuria/tratamiento farmacológico , Alcaptonuria/genética , Alcaptonuria/metabolismo , Simulación del Acoplamiento Molecular , Ocronosis/tratamiento farmacológico , Ácido Homogentísico/metabolismoRESUMEN
Hyperpigmentation is the most common complaint in the age group 40-45 years, seeking consultation for skin disorders. Hydroquinone is a commonly used depigmenting agent in clinical practice for treating hyperpigmentation. Prolonged use of hydroquinone has been associated with cancer risk and exogenous ochronosis. The CARES (The Coronavirus Aid, Relief, and Economic Security Act) Act of 2020 has instituted significant changes to hydroquinone containing OTC (over the counter) products, and consequently, many hydroquinone-based OTC products had to be withdrawn from the market. Henceforth, products containing hydroquinone would need US Food and Drug Administration approval via new drug application pathways for commercialization. Alternative treatment options to hydroquinone in clinical practice are reviewed in this paper with regard to their safety and efficacy vis a vis hydroquinone. Also, new potential treatment options such as thiamidol, Polypodium leucotomos, and glutathione are discussed. The review shows that these alternative depigmenting agents can be rationally combined to achieve desired treatment goals in the management of hyperpigmentation.
Asunto(s)
Hiperpigmentación , Ocronosis , Humanos , Adulto , Persona de Mediana Edad , Hidroquinonas/efectos adversos , Hiperpigmentación/inducido químicamente , Hiperpigmentación/tratamiento farmacológico , Ocronosis/inducido químicamente , Ocronosis/diagnóstico , Ocronosis/tratamiento farmacológicoRESUMEN
A large alkaptonuria (AKU) cohort was studied to better characterize the poorly understood spondyloarthropathy of rare disease AKU. Eighty-seven patients attended the National Alkaptonuria Centre (NAC) between 2007 and 2020. Seven only attended once. Fifty-seven attended more than once and received nitisinone 2 mg daily. Twenty-three attended at least twice without receiving nitisinone. Assessments included questionnaire analysis, 18F Positron emission tomography computerised tomography (PETCT), as well as photographs of ochronotic pigment in eyes and ears at baseline when 2 mg nitisinone was commenced and yearly thereafter. Blood and urine samples were collected for chemical measurement. The prevalence of ochronosis, as well as pain, PETCT and combined pain and PETCT scores, was greatly increased at 90.5%, 85.7%, 100%, and 100%, respectively. Joint pain scores were greatest in proximal joints in upper and lower limbs. PETCT joint scores were higher in proximal joints in upper limb but higher in distal joints in the lower limb. Spine pain scores were highest in lumbar, followed by cervical, thoracic, and cervical regions at 77.4%, 59.5%, 46.4%, and 25%, respectively. PETCT spine scores were highest in thoracic followed by lumbar, cervical, and sacroiliac regions at 74.4%, 70.7%, 64.6%, and 47.8% respectively; ochronosis associated closely with spondyloarthropathy scores (R = .65; P < .0001). Nitisinone reversed ochronosis significantly, with a similar pattern of decreased joint and spine disease. Spondyloarthropathy is a highly prevalent feature in this NAC cohort. Ochronosis appears to be associated with spondyloarthropathy. Nitisinone decreases ochronosis and had a similar nonsignificant effect pattern on spondyloarthropathy.
Asunto(s)
Alcaptonuria/tratamiento farmacológico , Ciclohexanonas/administración & dosificación , Ácido Homogentísico/metabolismo , Articulaciones/patología , Nitrobenzoatos/administración & dosificación , Ocronosis/tratamiento farmacológico , Columna Vertebral/patología , Anciano , Alcaptonuria/metabolismo , Estudios de Cohortes , Femenino , Humanos , Articulaciones/diagnóstico por imagen , Modelos Lineales , Masculino , Persona de Mediana Edad , Ocronosis/metabolismo , Fenotipo , Tomografía Computarizada por Tomografía de Emisión de Positrones , Índice de Severidad de la Enfermedad , Columna Vertebral/diagnóstico por imagen , Reino UnidoRESUMEN
Alkaptonuria (AKU) is an ultra-rare disease caused by the deficient activity of homogentisate 1,2-dioxygenase enzyme, leading the accumulation of homogentisic acid (HGA) in connective tissues implicating the formation of a black pigmentation called "ochronosis." Although AKU is a multisystemic disease, the most affected tissue is the articular cartilage, which during the pathology appears to be highly damaged. In this study, a model of alkaptonuric chondrocytes and cartilage was realized to investigate the role of HGA in the alteration of the extracellular matrix (ECM). The AKU tissues lost its architecture composed of collagen, proteoglycans, and all the proteins that characterize the ECM. The cause of this alteration in AKU cartilage is attributed to a degeneration of the cytoskeletal network in chondrocytes caused by the accumulation of HGA. The three cytoskeletal proteins, actin, vimentin, and tubulin, were analyzed and a modification in their amount and disposition in AKU chondrocytes model was identified. Cytoskeleton is involved in many fundamental cellular processes; therefore, the aberration in this complex network is involved in the manifestation of AKU disease.
Asunto(s)
Cartílago Articular/efectos de los fármacos , Condrocitos/efectos de los fármacos , Citoesqueleto/efectos de los fármacos , Matriz Extracelular/efectos de los fármacos , Ácido Homogentísico/farmacología , Actinas/efectos de los fármacos , Actinas/metabolismo , Alcaptonuria/metabolismo , Cartílago Articular/metabolismo , Condrocitos/metabolismo , Citoesqueleto/metabolismo , Matriz Extracelular/metabolismo , Humanos , Microtúbulos/efectos de los fármacos , Microtúbulos/metabolismo , Ocronosis/tratamiento farmacológico , Vimentina/efectos de los fármacos , Vimentina/metabolismoRESUMEN
Arthroplasty in the spondyloarthropathy (SPOND) of alkaptonuria (AKU) in incompletely characterised. The aim was to improve the understanding of arthroplasty in AKU through a study of patients attending the National Alkaptonuria Centre (NAC). Eighty-seven patients attended the NAC between 2007 and 2020. Seven only attended once. Fifty-seven attended more than once and received nitisinone 2 mg daily. Twenty-three attended at least twice without receiving nitisinone. Assessments including questionnaire analysis eliciting details of arthroplasty and other surgical treatments for SPOND, 18 FPETCT and CT densitometry at the neck of hip and lumbar spine, as well as photographs of the eyes and ears were acquired from patients attending the National Alkaptonuria Centre (NAC) at baseline when 2 mg nitisinone was commenced, and yearly thereafter. Photographs were scored to derive ochronosis scores. Blood and urine samples were collected for chemical analyses. The prevalence of arthroplasty was 36.8%, similar in males and females, occurring especially in the knees, hips and shoulders. Multiple arthroplasties were found in 29 patients (33.3%) in this cohort. Incident arthroplasty was 6.5% in the nitisinone group and 7.1% in the no-nitisinone group. Incident arthroplasty was 11.3% in the group with baseline arthroplasty and 3.51% in the group without. A strong association of arthroplasty with SPOND (R = 0.5; P << .0001) and ochronosis (R = 0.54; P < .0001) was seen. Nitisinone had no significant effect on incident arthroplasty. Arthroplasty due to ochronosis and SPOND is common in AKU. Nitisinone decreased ochronosis but had no effect on arthroplasty in this cohort.
Asunto(s)
Alcaptonuria/complicaciones , Artroplastia/estadística & datos numéricos , Ocronosis/complicaciones , Espondiloartropatías/diagnóstico por imagen , Espondiloartropatías/cirugía , Anciano , Alcaptonuria/tratamiento farmacológico , Estudios de Cohortes , Ciclohexanonas/administración & dosificación , Femenino , Humanos , Modelos Lineales , Masculino , Persona de Mediana Edad , Nitrobenzoatos/administración & dosificación , Ocronosis/tratamiento farmacológico , Tomografía Computarizada por Tomografía de Emisión de Positrones , Reino UnidoAsunto(s)
Ocronosis , Espondilitis Anquilosante , Humanos , Proteína Antagonista del Receptor de Interleucina 1/uso terapéutico , Ocronosis/diagnóstico por imagen , Ocronosis/tratamiento farmacológico , Radiografía , Columna Vertebral , Espondilitis Anquilosante/diagnóstico por imagen , Espondilitis Anquilosante/tratamiento farmacológicoRESUMEN
Alkaptonuria (AKU) is a disease caused by a deficient homogentisate 1,2-dioxygenase activity leading to systemic accumulation of homogentisic acid (HGA), that forms a melanin-like polymer that progressively deposits onto connective tissues causing a pigmentation called "ochronosis" and tissue degeneration. The effects of AKU and ochronotic pigment on the biomechanical properties of articular cartilage need further investigation. To this aim, AKU cartilage was studied using thermal (thermogravimetry and differential scanning calorimetry) and rheological analysis. We found that AKU cartilage had a doubled mesopore radius compared to healthy cartilage. Since the mesoporous structure is the main responsible for maintaining a correct hydrostatic pressure and tissue homoeostasis, drastic changes of thermal and rheological parameters were found in AKU. In particular, AKU tissue lost its capability to enhance chondrocytes metabolism (decreased heat capacity) and hence the production of proteoglycans. A drastic increase in stiffness and decrease in dissipative and lubricant role ensued in AKU cartilage. Multiphoton and scanning electron microscopies revealed destruction of cell-matrix microstructure and disruption of the superficial layer. Such observations on AKU specimens were confirmed in HGA-treated healthy cartilage, indicating that HGA is the toxic responsible of morphological and mechanical alterations of cartilage in AKU.
Asunto(s)
Alcaptonuria/tratamiento farmacológico , Condrocitos/efectos de los fármacos , Ácido Homogentísico/farmacología , Ocronosis/tratamiento farmacológico , Alcaptonuria/metabolismo , Cartílago Articular/efectos de los fármacos , Cartílago Articular/metabolismo , Condrocitos/metabolismo , Humanos , Oxidación-Reducción/efectos de los fármacos , Pigmentación/efectos de los fármacosRESUMEN
QUESTION: Does Nitisinone prevent the clinical progression of the Alkaptonuria? FINDINGS: In this observational study on 39 patients, 2â¯mg of daily nitisinone inhibited ochronosis and significantly slowed the progression of AKU over a three-year period. MEANING: Nitisinone is a beneficial therapy in Alkaptonuria. BACKGROUND: Nitisinone decreases homogentisic acid (HGA), but has not been shown to modify progression of Alkaptonuria (AKU). METHODS: Thirty-nine AKU patients attended the National AKU Centre (NAC) in Liverpool for assessments and treatment. Nitisinone was commenced at V1 or baseline. Thirty nine, 34 and 22 AKU patients completed 1, 2 and 3â¯years of monitoring respectively (V2, V3 and V4) in the VAR group. Seventeen patients also attended a pre-baseline visit (V0) in the VAR group. Within the 39 patients, a subgroup of the same ten patients attended V0, V1, V2, V3 and V4 visits constituting the SAME Group. Severity of AKU was assessed by calculation of the AKU Severity Score Index (AKUSSI) allowing comparison between the pre-nitisinone and the nitisinone treatment phases. RESULTS: The ALL (sum of clinical, joint and spine AKUSSI features) AKUSSI rate of change of scores/patient/month, in the SAME group, was significantly lower at two (0.32⯱â¯0.19) and three (0.15⯱â¯0.13) years post-nitisinone when compared to pre-nitisinone (0.65⯱â¯0.15) (pâ¯<â¯.01 for both comparisons). Similarly, the ALL AKUSSI rate of change of scores/patient/month, in the VAR group, was significantly lower at one (0.16⯱â¯0.08) and three (0.19⯱â¯0.06) years post-nitisinone when compared to pre-nitisinone (0.59⯱â¯0.13) (pâ¯<â¯.01 for both comparisons). Combined ear and ocular ochronosis rate of change of scores/patient/month was significantly lower at one, two and three year's post-nitisinone in both VAR and SAME groups compared with pre-nitisinone (pâ¯<â¯.05). CONCLUSION: This is the first indication that a 2â¯mg dose of nitisinone slows down the clinical progression of AKU. Combined ocular and ear ochronosis progression was arrested by nitisinone.
Asunto(s)
Alcaptonuria/tratamiento farmacológico , Ciclohexanonas/administración & dosificación , Nitrobenzoatos/administración & dosificación , Ocronosis/tratamiento farmacológico , 4-Hidroxifenilpiruvato Dioxigenasa/metabolismo , Alcaptonuria/epidemiología , Alcaptonuria/metabolismo , Alcaptonuria/patología , Progresión de la Enfermedad , Femenino , Ácido Homogentísico/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Ocronosis/epidemiología , Ocronosis/metabolismo , Ocronosis/patología , Reino UnidoRESUMEN
Alkaptonuria (AKU) is caused by deficiency of the enzyme homogentisate 1,2 dioxygenase. It results in an accumulation of homogentisate which oxidizes spontaneously to benzoquinone acetate, a highly oxidant compound, which polymerises to a melanin-like structure, in a process called ochronosis. Asymptomatic during childhood, this accumulation will lead from the second decade of life to a progressive and severe spondylo-arthopathy, associated with multisystem involvement: osteoporosis/fractures, stones (renal, prostatic, gall bladder, salivary glands), ruptures of tendons/muscle/ligaments, renal failure and aortic valve disease. The pathophysiological mechanisms of AKU remain poorly understood, but recent advances lead us to reconsider the treatment strategy in AKU patients. Besides the supporting therapies (pain killers, anti-inflammatory drugs, physiotherapy, joints replacements and others), specific therapies have been considered (anti-oxidant, low protein diet, nitisinone), but clinical studies have failed to prove efficiency on the rheumatological lesions of the disease. Here we propose a treatment strategy for children and adults with AKU, based on a review of the latest findings on AKU and lessons from other aminoacipathies, especially tyrosinemias.
Asunto(s)
Alcaptonuria/tratamiento farmacológico , Adulto , Factores de Edad , Alcaptonuria/dietoterapia , Alcaptonuria/epidemiología , Antioxidantes/uso terapéutico , Niño , Ciclohexanonas/uso terapéutico , Humanos , Nitrobenzoatos/uso terapéutico , Ocronosis/dietoterapia , Ocronosis/tratamiento farmacológico , Ocronosis/epidemiología , Fenilalanina/administración & dosificación , Tirosina/administración & dosificaciónRESUMEN
The congenital form of ochronosis is a result of the rare autosomal recessive inherited metabolic disease alkaptonuria. The disruption of tyrosine metabolism based on a genetic defect in the enzyme homogentisate dioxygenase results in accumulation of homogentisic acid (HA) which is excreted in the urine and leads to a dark discoloration after a certain incubation time at room temperature. Furthermore, HA polymerizes forming a pigment that is deposited in connective tissues such as tendons, cartilage, bones, intervertebral discs, sclerae, ossicles, cardiac valves and coronary arteries and leads to dark brown discoloration and degeneration. The case of a 74-year-old female patient with ochronosis and classical manifestations is described and in addition a current overview of this rare disease is provided.
Asunto(s)
Alcaptonuria/complicaciones , Alcaptonuria/diagnóstico , Ocronosis/complicaciones , Ocronosis/diagnóstico , Osteoartritis/diagnóstico , Osteoartritis/etiología , Anciano , Alcaptonuria/tratamiento farmacológico , Antiinflamatorios no Esteroideos/uso terapéutico , Antirreumáticos/uso terapéutico , Terapia Combinada , Diagnóstico Diferencial , Femenino , Humanos , Ocronosis/tratamiento farmacológico , Osteoartritis/tratamiento farmacológico , Modalidades de Fisioterapia , Resultado del TratamientoRESUMEN
BACKGROUND: Alkaptonuria (AKU) is a rare metabolic disease caused by deficiency of homogentisate 1,2 dioxygenase, an enzyme involved in tyrosine catabolism, resulting in increased circulating homogentisic acid (HGA). Over time HGA is progressively deposited as a polymer (termed ochronotic pigment) in collagenous tissues, especially the cartilages of weight bearing joints, leading to severe joint disease. OBJECTIVES: To characterise blood biochemistry and arthropathy in the AKU mouse model (Hgd-/-). To examine the therapeutic effect of long-term treatment with nitisinone, a potent inhibitor of the enzyme that produces HGA. METHODS: Lifetime levels of plasma HGA from AKU mice were measured by high-performance liquid chromatography (HPLC). Histological sections of the knee joint were examined for pigmentation. The effect of nitisinone treatment in both tissues was examined. RESULTS: Mean (±SE) plasma HGA levels were 3- to 4-fold higher (0.148±0.019 mM) than those recorded in human AKU. Chondrocyte pigmentation within the articular cartilage was first observed at 15 weeks, and found to increase steadily with mouse age. Nitisinone treatment reduced plasma HGA in AKU mice throughout their lifetime, and completely prevented pigment deposition. CONCLUSIONS: The AKU mouse was established as a model of both the plasma biochemistry of AKU and its associated arthropathy. Early-stage treatment of AKU patients with nitisinone could prevent the development of associated joint arthropathies. The cellular pathology of ochronosis in AKU mice is identical to that observed in early human ochronosis and thus is a model in which the early stages of joint pathology can be studied and novel interventions evaluated.
Asunto(s)
Ciclohexanonas/farmacología , Inhibidores Enzimáticos/farmacología , Artropatías/tratamiento farmacológico , Artropatías/fisiopatología , Nitrobenzoatos/farmacología , Ocronosis/tratamiento farmacológico , Ocronosis/fisiopatología , 4-Hidroxifenilpiruvato Dioxigenasa/antagonistas & inhibidores , 4-Hidroxifenilpiruvato Dioxigenasa/sangre , 4-Hidroxifenilpiruvato Dioxigenasa/genética , Alcaptonuria , Animales , Condrocitos/efectos de los fármacos , Condrocitos/patología , Modelos Animales de Enfermedad , Femenino , Humanos , Artropatías/genética , Articulación de la Rodilla/patología , Articulación de la Rodilla/fisiopatología , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Noqueados , Ocronosis/genéticaAsunto(s)
Ácido Hialurónico/administración & dosificación , Ácido Hialurónico/uso terapéutico , Ocronosis/tratamiento farmacológico , Osteoartritis/tratamiento farmacológico , Adyuvantes Inmunológicos/administración & dosificación , Adyuvantes Inmunológicos/uso terapéutico , Adulto , Comorbilidad , Femenino , Humanos , Inyecciones Intraarticulares , Ocronosis/epidemiología , Ocronosis/patología , Osteoartritis/epidemiología , Osteoartritis/patología , Resultado del TratamientoRESUMEN
Alkaptonuria (AKU) is due to excessive homogentisic acid accumulation in body fluids due to lack of enzyme homogentisate dioxygenase leading in turn to varied clinical manifestations mainly by a process of conversion of HGA to a polymeric melanin-like pigment known as ochronosis. A potential treatment, a drug called nitisinone, to decrease formation of HGA is available. However, successful demonstration of its efficacy in modifying the natural history of AKU requires an effective quantitative assessment tool. We have described two potential tools that could be used to quantitate disease burden in AKU. One tool describes scoring the clinical features that includes clinical assessments, investigations and questionnaires in 15 patients with AKU. The second tool describes a scoring system that only includes items obtained from questionnaires used in 44 people with AKU. Statistical analyses were carried out on the two patient datasets to assess the AKU tools; these included the calculation of Chronbach's alpha, multidimensional scaling and simple linear regression analysis. The conclusion was that there was good evidence that the tools could be adopted as AKU assessment tools, but perhaps with further refinement before being used in the practical setting of a clinical trial.
Asunto(s)
Alcaptonuria/diagnóstico , Alcaptonuria/epidemiología , Ácido Homogentísico/metabolismo , Ocronosis/diagnóstico , Ocronosis/epidemiología , Índice de Severidad de la Enfermedad , Adolescente , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Alcaptonuria/tratamiento farmacológico , Alcaptonuria/enzimología , Causalidad , Estudios de Cohortes , Comorbilidad , Ciclohexanonas/uso terapéutico , Femenino , Homogentisato 1,2-Dioxigenasa/deficiencia , Humanos , Hipertensión/epidemiología , Masculino , Persona de Mediana Edad , Nitrobenzoatos/uso terapéutico , Ocronosis/tratamiento farmacológico , Ocronosis/enzimología , Dolor/epidemiología , Análisis de Regresión , Reproducibilidad de los Resultados , Distribución por Sexo , Fumar/epidemiología , Encuestas y CuestionariosRESUMEN
Alkaptonuria (AKU) is a rare autosomal recessive disease, associated with deficiency of homogentisate 1,2-dioxygenase activity in the liver. This leads to an accumulation of homogentisic acid (HGA) and its oxidized derivatives in polymerized form in connective tissues especially in joints. Currently, AKU lacks an appropriate therapy. Hence, we propose a new treatment for AKU using the antioxidant N-acetylcysteine (NAC) administered in combinations with ascorbic acid (ASC) since it has been proven that NAC counteracts the side-effects of ASC. We established an in vitro cell model using human articular primary chondrocytes challenged with an excess of HGA (0.33 mM). We used this experimental model to undertake pre-clinical testing of potential antioxidative therapies for AKU, evaluating apoptosis, viability, proliferation, and metabolism of chondrocytes exposed to HGA and treated with NAC and ASC administered alone or in combination addition of both. NAC decreased apoptosis induced in chondrocytes by HGA, increased chondrocyte growth reduced by HGA, and partially restored proteoglycan release inhibited by HGA. A significantly improvement in efficacy was found with combined addition of the two antioxidants in comparison with NAC and ASC alone. Our novel in vitro AKU model allowed us to demonstrate the efficacy of the co-administration of NAC and ASC to counteract the negative effects of HGA for the treatment of ochronotic arthropathy.
Asunto(s)
Acetilcisteína/uso terapéutico , Alcaptonuria/tratamiento farmacológico , Antioxidantes/uso terapéutico , Ácido Ascórbico/uso terapéutico , Ocronosis/tratamiento farmacológico , Acetilcisteína/farmacología , Alcaptonuria/enzimología , Alcaptonuria/patología , Antioxidantes/farmacología , Apoptosis/efectos de los fármacos , Ácido Ascórbico/farmacología , Cartílago Articular/citología , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Condrocitos/efectos de los fármacos , Condrocitos/metabolismo , Homogentisato 1,2-Dioxigenasa/genética , Homogentisato 1,2-Dioxigenasa/metabolismo , Ácido Homogentísico/metabolismo , Humanos , Ocronosis/enzimología , Ocronosis/patología , Carbonilación ProteicaRESUMEN
OBJECTIVES: Alkaptonuria (AKU) is a rare genetic disease associated with deficient homogentisate 1,2-dioxygenase activity in the liver. This leads to the accumulation of homogentisic acid (HGA) and its oxidized/polymerized products in connective tissues, which in turn become characterized by the presence of melanin-like pigments (ochronosis). Since at present, further studies are necessary to support the use of drugs for the treatment of AKU, we investigated the effects of various anti-oxidants in counteracting melanin-like pigmentation and oxidative stress related to HGA and its metabolites. METHODS: We set up an in vitro model using human serum treated with 0.33 mM HGA and tested the anti-oxidants ascorbic acid, N-acetylcysteine, phytic acid (PHY), taurine (TAU), ferulic acid (FER) and lipoic acid (LIP) for their ability to prevent or delay the production of melanin-like pigments, as well as to reduce oxidative post-translational modifications of proteins. Monitoring of intrinsic fluorescence of HGA-induced melanin-like pigments was used to evaluate the efficacy of compounds. RESULTS: Our model allowed us to prove efficacy especially for PHY, TAU, LIP and FER in counteracting the production of HGA-induced melanin-like pigments and protein oxidation induced by HGA and its metabolites. CONCLUSIONS: Our model allows the opening of new anti-oxidant therapeutic strategies to treat alkaptonuric ochronosis.
Asunto(s)
Alcaptonuria/tratamiento farmacológico , Antioxidantes/uso terapéutico , Ácido Homogentísico/metabolismo , Ocronosis/tratamiento farmacológico , Estrés Oxidativo/efectos de los fármacos , Carbonilación Proteica/efectos de los fármacos , Acetilcisteína/uso terapéutico , Ácido Ascórbico/uso terapéutico , Células Cultivadas , Ácidos Cumáricos/uso terapéutico , Humanos , Ácido Fítico/uso terapéutico , Taurina/uso terapéutico , Ácido Tióctico/uso terapéuticoAsunto(s)
Articulación de la Rodilla/patología , Ocronosis/diagnóstico , Tendinopatía/diagnóstico , Tendones/patología , Artritis Reumatoide/diagnóstico , Diagnóstico Diferencial , Quimioterapia Combinada , Ácido Homogentísico/orina , Humanos , Articulación de la Rodilla/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Ocronosis/complicaciones , Ocronosis/tratamiento farmacológico , Sinovitis/diagnóstico , Sinovitis/etiología , Tendinopatía/complicaciones , Tendones/diagnóstico por imagen , UltrasonografíaRESUMEN
Endogenous ochronosis or alkaptonuria is a rare, autosomal recessive disease of tyrosine metabolism that is caused by a deficiency of the enzyme homogentisic acid oxidase. The disease results in the accumulation and deposition of homogentisic acid in the cartilage, eyelids, forehead, cheeks, axillae, genital region, buccal mucosa, larynx, tympanic membranes, and tendons. The disease generally presents in adults with arthritis and skin abnormalities; occasionally, involvement of other organs may be seen. A 49-year-old man was referred to our clinic with verrucous lesions on his hands. On physical examination, caviar-like ochronotic papules were found around his eyes and the helix cartilage of his ears, and on the dorsa of both hands. There were brown macules on the sclera (Osler's sign). The patient had arthritis and nephrolithiasis, and a sample of his urine darkened upon standing. Histopathological examination showed deposition of ochronotic pigment. High-dose ascorbic acid was given, and the patient showed improvement on follow-up examination 6 months later.